If you believe the grand promises, it sounds simple:
AI detects patterns, calculates probabilities, simulates scenarios — and delivers the perfect stock trades. But what happens when you stop testing those predictions on a screen and start trading with real money?
That’s exactly what I did. Five trades. Five stories. Between them: euphoria, hard landings, one stop-loss that kicked me out brutally — and the realization of how mercilessly the market corrects AI dreams.
1. Insmed Incorporated (INSM) – The Perfect Start (August 12, 2025)
Brensocatib, a new drug for bronchiectasis, was awaiting FDA approval. My AI model gave it a clear bullish probability.
I entered — and it was right. On August 12, the stock closed at $122, up roughly 8% from the previous day.
A flawless opening to my experiment. A first victory — and a dangerous dose of confidence.
2. Tonix Pharmaceuticals Holding Corp. (TNXP) – FDA Blessing, Investor Curse (August 15–19, 2025)
With Tonix, I expected another winner. FDA approval for Tonmya, a fibromyalgia therapy, on August 15 — how could that not rise?
Instead, disaster: on approval day, the stock plunged after hours to $40.07.
The next day, my stop-loss triggered — brutally, without a chance to react. By August 19, it had fallen to $36.53.
Loss: –13.7%. A brutal insight: FDA approval doesn’t equal stock approval.
A stop-loss saves you from a total crash — but sometimes also from every recovery.
3. Ionis Pharmaceuticals (IONS) – A Firework That Never Lit (August 15, 2025)
That same day, Ionis received FDA approval for Olezarsen. My AI and I expected a rally. And yes — approved! But the price barely moved: from $42.85 to $43.78, then $43.43.
Some intraday flicker, but no real fire. Lesson: Positive news ≠ guaranteed rally.
What matters is how much was already priced in — and how fast investors take profits.
Sometimes, an “approval” fades like a match in the wind.
4. Palantir Technologies Inc. (PLTR) – Brief Euphoria (August 7–12, 2025)
“Government contracts, AI story — 70% chance of a surge,” whispered my AI. On August 7, Q2 earnings came in. The stock jumped intraday to nearly $29 (≈ $184 post-split), closing at $28.9, about +6%.
Yet only days later, Palantir drifted back to $27.5 (≈ $156 post-split).
Lesson: AI can detect hype — but not how quickly it evaporates.
5. NVIDIA Corporation (NVDA) – Records Without a Rally (August 27–28, 2025)
The world saw Nvidia as the AI winner. So did my AI: bullish, bullish, bullish.
On August 27, Nvidia reported record revenues. The stock? Flat — $181.60, unchanged. The next day: $180.17, later even $175. Classic sell-the-news.
Record numbers, zero euphoria. I closed the trade slightly in the red.
Conclusion – Between Euphoria and Reality
Five trades. Five lessons.
✅ One clear win (Insmed)
❌ One brutal fall (Tonix)
💥 One FDA firework that fizzled (Ionis)
📈 One mini-rally that vanished (Palantir)
💾 And one record that didn’t move markets (Nvidia)
In the end, I’m slightly positive — thanks to Insmed and Palantir. But far more valuable is the lesson: how ruthless reality becomes when you follow AI predictions blindly.
So, can AI beat the market?
Not really. But it can force you to follow your own rules.
Mag. Nevena Shotekova-Zöchling
Editor-in-Chief & Publisher of Article Zero
(This is not financial advice. The trades described were real — complete with excitement, face-plants, and a stop-loss that hit harder than a bouncer in a Vienna nightclub. Reproducing them is at your own risk. Gains not guaranteed. Losses highly probable. In short: feel free to laugh, but invest with your brain.)
